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Abstract
Background: Phosphoproteins play important roles in a vast series of biological processes. Recent
proteomic technologies offer the comprehensive analyses of phosphoproteins. Recently, we
demonstrated that surface-enhanced laser desorption/ionization time of flight mass (SELDI-TOF
MS) would detect phosphoproteins quantitatively, which was a new application of SELDI-TOF MS.
Results: We combined immobilized metal affinity chromatography (IMAC) with SELDI-TOF MS.
After SELDI-TOF MS analysis of IMAC-enrichment phosphoproteins from A549 cancer cells, a
series of protein peaks at 12.9, 12.8, 12.7 and 12.6 kDa was obtained in a mass spectrum. The peak
intensities of these proteins decreased after a phosphatase treatment and, interestingly, they also
decreased when the cells were pre-treated with a novel phosphatidylinositol 3-kinase (PI3K)
inhibitor, ZSTK474, suggesting that these proteins were ZSTK474-sensitive phosphoproteins.
Identity of the phosphoproteins, which were predicted as the multi-phosphorylated forms of 4E-
binding protein 1 (4E-BP1) with the aid of TagIdent algorithm, was confirmed by
immunoprecipitation and subsequent SELDI-TOF MS analysis. 4E-BP1 is a downstream component
of the PI3K/Akt/mTOR pathway and it regulates protein synthesis. We also investigated the effect
of ZSTK474 on 4E-BP1 phosphorylation using phospho-specific antibodies. ZSTK474, which have
little inhibitory activity for mTOR, inhibited phosphorylation of Ser65, Thr70 and Thr37/46 in 4E-
BP1. In contrast, rapamycin, an inhibitor of mTOR, blocked phosphorylation only of Ser65 and
Thr70. These results suggest that ZSTK474 and rapamycin inhibited the phosphorylation of 4E-BP1
in a different manner.
Conclusion:  We identified a group of ZSTK474-sensitive phosphoproteins as the multi-
phosphorylated form of 4E-BP1 by combining IMAC, SELDI-TOF MS and antibodies.
Background
Phosphoproteins are involved in numerous signaling
pathways in living cells. Recent development of proteom-
ics-based technologies have provided many tools for ana-
lyzing phosphoproteins comprehensively [1-5]. One such
technology is surface-enhanced laser desorption-ioniza-
tion time-of-flight mass spectrometry (SELDI-TOF MS).
Recently, we and another group successfully used SELDI-
TOF MS to identify phosphoproteins in the crude cell
extracts [6,7]. We further demonstrated that SELDI-TOF
Published: 31 March 2009
Proteome Science 2009, 7:14 doi:10.1186/1477-5956-7-14
Received: 24 September 2008
Accepted: 31 March 2009
This article is available from: http://www.proteomesci.com/content/7/1/14
© 2009 Akashi and Yamori; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Proteome Science 2009, 7:14 http://www.proteomesci.com/content/7/1/14
Page 2 of 8
(page number not for citation purposes)
MS could quantitatively detect phosphoproteins [8] and
identify phosphorylated sites of a phosphoprotein [8].
Class I phosphatidylinositol 3-kinase (PI3K), a het-
erodimer comprised of the regulatory and catalytic subu-
nits, is a major signaling component downstream of
receptor tyrosine kinases. The PI3K signaling pathway is
frequently activated in various types of cancer cells, and is
believed to promote cell proliferation, growth, and sur-
vival [9]. Mutations and/or amplification of PI3K gene
have been found in human cancer cells derived from sev-
eral tissues [9,10]. Thus, PI3K is a potential target for the
development of drugs for cancer chemotherapy.
Although there are a number of PI3K inhibitors under
development [11-16], as of yet none of them has been
launched as an anticancer drug for clinical use. Recently,
we developed a potent novel PI3K inhibitor, ZSTK474
[11], which competitively blocked the binding of ATP to
the catalytic subunit of all class I PI3K isoforms [17], but
did not significantly inhibit the activity of 140 other pro-
tein kinases including that of mTOR [11,17]. Further-
more, ZSTK474 inhibited several human cancer
xenografts without severe toxicity [11]. Since it will be an
advantage to know whether a potential drug is suitable for
clinical use, a detailed knowledge of the molecular phar-
macology of ZSTK474 is necessary to achieve this goal.
The aim of this study was to identify phosphoproteins
whose phosphorylations were sensitive to ZSTK474 by
combining immobilized metal affinity chromatography
(IMAC) with SELDI-TOF MS and to investigate the effect
of ZSTK474 on the phosphorylations in human cancer
cells. In the present study, we identified a group of
ZSTK474-sensitive phosphoproteins as the multi-phos-
phorylated form of 4E-binding protein 1 (4E-BP1).
Results and discussion
Analysis of phosphoprotein profiles by SELDI-TOF MS
In order to efficiently capture and detect phosphoproteins
by SELDI-TOF MS, we first purified and concentrated
phosphoproteins from the lysate of A549 human lung
cancer cells using IMAC resins. The eluted proteins from
the resins were applied onto a strong anion-exchange
array (Q10 chip) and subsequently analyzed by SELDI-
TOF MS. As a result of this analysis, we also obtained sev-
eral multi-peak containing protein profiles (data not
shown). Since the mass of a phosphate group is 80 Da,
dephosphorylation by a phosphatase would be expected
to shift the peak of a phosphoprotein by a mass of 80 Da
× n (where n is the number of phosphorylated sites) less
than the original peak. Previously, we identified the phos-
phorylated form of the ribosomal P2 protein from crude
extracts by using the SELDI-TOF MS technique [6]. In the
present study also we obtained similar result (Fig. 1A).
The single peak at 11.6 kDa in Fig. 1A-b is the non-phos-
phorylated form of ribosomal P2 according to our previ-
ous analysis. The 11.7 and 11.8 kDa proteins in Fig. 1A-a
are the mono- and di- phosphorylated ribosomal P2,
respectively, as the two protein peaks converged into a sin-
gle peak after the λ-PPase treatment in Fig. 1A-b. Simi-
larly, we detected several phosphoprotein candidates
whose peaks disappeared when treated with λ-PPase (data
not shown). We analyzed only intact proteins that were
not treated with proteases. It might be possible that many
phosphoproteins did not fall in the detectable range of
SELDI-TOF MS in the present conditions. Among those
phosphoprotein candidates, a series of 12.9, 12.8, 12.7
and 12.6 kDa proteins might be multi-phosphorylated
forms of a protein, since the mass difference between each
adjacent protein peak was 80 Da (Fig. 1B-a). Furthermore,
λ-PPase treatment decreased these peak intensities and
concomitantly increased the peak intensity at 12.5 kDa
(12,471 Da in Fig. 1B-b) which was about 400 Da (80 Da
× 5) smaller than the 12.9 kDa (12,875 Da in Fig. 1B-a),
suggesting that the 12.5 kDa (12,471 Da in Fig. 1B-b) and
12.9 kDa (12,875 Da in Fig. 1B-a) proteins were the orig-
inal one containing non-phosphorylated 5 phosphoryla-
tion sites and its penta-phosphorylated form, respectively.
The peaks at 12.6 kDa (12,590 Da) and 12.7 kDa (12,694
Da) in Fig. 1B-b turn out to be derived from the λ-PPase,
because the corresponding peaks (12,598 and 12,698 Da
in Fig. 1B-c) were observed when λ-PPase alone was ana-
lyzed on the chip.
Screening of ZSTK474-sensitive phosphoproteins
Among the candidate phosphoproteins, we next searched
for the ZSTK474-sensitive phosphoproteins. When pro-
teins were purified by IMAC from the ZSTK474-treated
A549 cell extract and subsequently analyzed by SELDI-
TOF MS, we found that the intensity of the 12.9 kDa pro-
tein peak was remarkably reduced in a dose dependent
manner (Figs. 1B-d, e). In addition, the peak intensities of
12.8 and 12.7 kDa proteins also obviously decreased
(Figs. 1B-d, e). These results implied that these proteins
were from a ZSTK474-sensitive phosphoprotein that con-
tained multiple phosphorylation sites. The peaks of ribos-
omal P2 protein (Fig. 1A-c) and the other phosphoprotein
candidates (data not shown), however, remained
unchanged upon ZSTK474 treatment, suggesting that the
phosphorylation of these proteins were not affected by
ZSTK474.
Identification of the ZSTK474-sensitive phosphoproteins
We next used the TagIdent tool http://www.expasy.org/
tools/tagident.html, which searches for candidate pro-
teins from the Swiss-Prot database based on the input iso-
electric point (pI) and molecular weight (MW), to predict
the phosphoprotein candidates. Since the series of phos-
phoproteins was detected on the strong anion-exchange
arrays (Q10 chip), we roughly estimated the pI of the tar-
gets within the acidic pH region, that is from 3.0 to 7.0.Proteome Science 2009, 7:14 http://www.proteomesci.com/content/7/1/14
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Analysis of phosphoprotein profiles by SELDI-TOF MS Figure 1
Analysis of phosphoprotein profiles by SELDI-TOF MS. Lysate from A549 cells was purified by IMAC resins and subse-
quently analyzed by SELDI-TOF MS as described in Methods. Two regions of SELDI-TOF MS spectra were shown (A and B). 
The eluate from the IMAC resin was treated without (A-a, B-a) or with (A-b, B-b) λ-PPase for 1 hr at 30°C, and then was 
applied onto the Q10 chips. The mass spectrum of the sole λ-PPase protein was also analyzed by SELDI-TOF MS (B-c). The 
A549 cells pre-treated with 0.5 μM (B-d) and 1.5 μM (A-c, B-e) of ZSTK474 for 30 min were lysed and processed for analysis 
by SELDI-TOF MS. The intensity of the 12.9 kDa protein peak decreased by ZSTK474 treatment in a dose dependent manner 
(B-a, d, and e). The left-right arrow indicates a mass difference of 80 Da that accounts for the MW of a phosphate group.
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Then, we inputted the hypothetic MW values that were 80
Da × n smaller than the 12.9 kDa (12,875 Da in Fig. 1B-
a), and searched the protein lists to find candidate phos-
phoproteins. When a pI of 5.0 (± 2.0) and a molecular
mass of 12,475 Da (± 0.5%) were inputted in the TagI-
dent, 30 proteins were listed in the specified pI/MW range.
Among these proteins, we noticed 4E-BP1 (accession no.
Q13541) and considered it as our target phosphopro-
teins, because the Swiss-Prot suggested that it could be
phosphorylated at multiple sites and also because it was
known to be a downstream component of the PI3K/Akt/
mTOR pathway [18].
To confirm that the series of phosphoproteins is indeed 4E-
BP1, we immunoprecipitated 4E-BP1 and its phosphor-
ylated forms from the extract of A549 cells transiently over-
expressing 4E-BP1 by using an anti-total-4E-BP1 antibody,
and analyzed the immunoprecipitated proteins by SELDI-
TOF MS after loading the immunoprecipitate onto a NP20
chip. As shown in Fig. 2a, a 12.9 kDa protein peak and
three other peaks, each differing from the 12.9 Da peak by
a mass of about 80 Da × n, were detected in the mass spec-
tra. When the immunoprecipitate was treated with λ-PPase
and subsequently analyzed by SELDI-TOF MS, a single
peak at 12.5 kDa, other than the peaks derived from the λ-
PPase, was observed (Fig. 2b). The mass difference between
the 12.9 and 12.5 kDa protein peaks was about 400 Da,
which corresponds to the sum of five phosphate groups (80
Da × 5). These results suggested that the target protein was
4E-BP1, and the 12.9 kDa protein peak was the penta-phos-
phorylated form of 4E-BP1. Although a MS/MS analysis is
needed to prove that a mass shift of 80 Da really indicate a
phosphorylation site, our experiments with a phosphatase
and antibodies make it very likely that the signals indeed
correspond to the suggested phosphoprotein.
Furthermore, when the A549 cells were pre-treated with
1.5 μM ZSTK474 for 30 min, and the cell extract was then
immunoprecipitated with the anti-total-4E-BP1 antibody
and subsequently analyzed by SELDI-TOF MS, a single
peak at 12.5 kDa was detected in the mass spectra of the
immunoprecipitate (Fig. 2d), suggesting that phosphor-
ylation of all sites in 4E-BP1 were inhibited by ZSTK474.
It is known that the hypophosphorylated 4E-BP1 binds to
the eukaryotic translation initiation factor 4E (eIF4E) that
recognizes the cap structure present at the 5' end of
mRNAs, resulting in inhibition of cap-dependent transla-
tion initiation [19]. Therefore, our results, as described
above, suggest that ZSTK474 may cause a reduction in
protein synthesis by inhibiting 4E-BP1 phosphorylation,
which in turn might lead to the slowing down of cell
growth/cell size [20] and cell cycle progression [21].
Inhibitory effect of ZSTK474 on 4E-BP1 phosphorylation
The regulation of 4E-BP1 phosphorylation at each poten-
tial phosphorylation-site is not clearly understood. There-
fore, we next analyzed the ZSTK474-mediated inhibition
of phosphorylation in 4E-BP1 (Ser65, Thr70, and Thr37/
46) and also in two other components in the PI3K path-
way, namely Akt (Ser473) and p70 S6 kinase (p70S6K)
(Thr389), using A549 cells overexpressing 4E-BP1 and
immunoblotting with phospho-specific antibodies (Fig.
3). The PI3K inhibitor ZSTK474 inhibited phosphoryla-
tion of Ser473 in Akt, Thr389 in p70S6K, as well as phos-
phorylation of all sites in 4E-BP1 (Fig. 3). In the case of
phosphorylation of Thr70 in p-4E-BP1, the lowest inhibi-
tor concentrations reduced the phosphorylation degree
significantly. However, no dose response was observed
(Fig. 3). Its molecular mechanism remains to be clarified.
On the other hand, the mTOR inhibitor rapamycin did
not inhibit the phosphorylation of Thr37/46 in 4E-BP1 or
that of Ser473 in Akt (Fig. 3), although it inhibited the
phosphorylation of Thr389 in p70S6K, and Ser65 and
Thr70 in 4E-BP1. These results suggest that ZSTK474 and
rapamycin differentially inhibited the phosphorylation of
4E-BP1. It seems quite reasonable because we previously
demonstrated that ZSTK474 did not inhibit mTOR
[11,17]. Rapamycin reportedly blocks the formation of
mTOR-rapter-4E-BP complex, which causes the inhibition
of the phosphorylation of Ser65 and Thr70, but not the
phosphorylation of Thr37/46 [22,23]. Unknown
kinase(s) could be responsible for the phosphorylation of
Thr37/46, and ZSTK474 might inhibit such unknown
pathways. However, the mechanism by which ZSTK474
caused the inhibition of 4E-BP at all the four sites remains
unknown. ZSTK474, which is a potent and narrow-spec-
trum PI3K inhibitor [11,17], might become an invaluable
tool for analyzing the mechanism in the future.
Conclusion
In this study, we developed an analytical method for iden-
tifying drug-sensitive phosphoproteins by combining
IMAC, SELDI-TOF MS and antibodies. By using this
method, we identified a series of phosphoproteins as the
multi-phosphorylated 4E-BP1 proteins whose phosphor-
ylation were inhibited by ZSTK474. This result suggested
that our method is useful to identify drug-sensitive phos-
phoproteins. In addition, we identified the phosphoryla-
tion status of 4E-BP1 at its multiple phosphorylation sites
by SELDI-TOF MS. These results together with our previ-
ous report [8] suggest that the SELDI-TOF MS technique is
an useful tool for quantitatively analyzing phosphopro-
teins. This technique can be applicable for analyzing other
post-translational modifications, such as phosphoryla-
tion, glycosylation, acetylation, etc.
Methods
Materials
ZSTK474 was provided by Zenyaku Kogyo Co. (Tokyo,
Japan). Rapamycin was purchased from Sigma (St. Louis,
MO, USA). Antibodies to phospho-Akt (Ser473) [25],
phospho-p70S6K (Thr389) [25], phospho-4E-BP1Proteome Science 2009, 7:14 http://www.proteomesci.com/content/7/1/14
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Immunoprecipitation and subsequent SELDI-TOF MS analysis of the target proteins Figure 2
Immunoprecipitation and subsequent SELDI-TOF MS analysis of the target proteins. Extracts prepared from the 
A549 cells overexpressing 4E-BP1 were first incubated with anti-total-4E-BP1 antibody and then with protein G agarose. The 
bound proteins were eluted from the resins as described in Methods. Eluate from the untreated cells (a), eluate treated with λ-
PPase for 1 hr at 30°C (b), and λ-PPase alone (c) were applied to NP20 chips and analyzed by SELDI-TOF MS. Lysate from the 
cells pre-treated with 1.5 μM ZSTK474 for 30 min was immunoprecipitated and processed for analysis by SELDI-TOF MS (d). 
The left-right arrow indicates a mass difference of 80 Da.
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Inhibitory effects of ZSTK474 on phosphoproteins Figure 3
Inhibitory effects of ZSTK474 on phosphoproteins. Phosphorylation of Akt (Ser473), p70S6K (Thr389), 4E-BP1 (Ser65, 
Thr70, Thr37/46) and total 4E-BP1 were measured in 4E-BP1 over-expressing A549 cells by immunoblotting with respective 
antibodies. The cells were treated with indicated concentrations of ZSTK474 (0.25, 0.5, 1, 2, and 4 μM) or rapamycin (0.1, 0.2, 
0.4, 0.8, and 1.6 μM) for 30 min. Intensity ratio of phosphorylated form/total form of 4E-BP1 was indicated under each lane. 
ZSTK474 inhibited phosphorylations of each downstream component of PI3K in a dose dependent manner. In contrast, 
rapamycin did not inhibit phosphorylation of Thr37/46 in 4E-BP1 as well as that of Ser473 in Akt.
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(Ser65) [24,25], phospho-4E-BP1 (Thr70) [24,25], phos-
pho-4E-BP1 (Thr37/46) [25], and total-4E-BP1 [25] were
purchased from Cell Signaling Technology (Beverly, MA,
USA) [24,25]. The phospho-Akt (Ser473) and 4E-BP1
(Ser65) antibodies were monoclonal, and the others were
polyclonal.
Cell culture and drug treatment
Human lung cancer cell line, A549, was cultured in RPMI
1640 supplemented with 5% fetal bovine serum and kan-
amycin (10 μg/ml) at 37°C in humidified air containing
5% CO2. Cells were seeded at 5 × 106 – 6.8 × 106 cells in
100-mm dish and grown over night. Cells were first prein-
cubated without or with the indicated concentration of a
given inhibitor (ZSTK474 or rapamycin) for 30 min, fol-
lowed by incubation with 10 ng/ml epidermal growth fac-
tor (EGF) for 10 min, and finally they were washed with
cold PBS and frozen in liquid N2.
IMAC
Phosphoproteins from cell lysate were purified with a
PhosphoProtein Purification Kit (QIAGEN, Hilden, Ger-
many) according to a modified version of the manufac-
turer's protocol. Briefly, frozen cells, collected from three
100-mm dishes for each treatment, were lysed with 1 ml
of a lysis buffer (QIAGEN) containing protease inhibitors,
benzonase and 0.5% (v/v) NP-40, and incubated for 30
min on ice. After centrifugation at 20,000 × g for 20 min,
the protein content of the supernatant was estimated
using a Protein Assay Kit (Bio-Rad Laboratories, Hercules,
USA), and the supernatant was then diluted to a protein
concentration of 0.1 mg/ml with the lysis buffer (QIA-
GEN) containing 0.25% (w/v) CHAPS. After performing
chromatography on the IMAC column following manu-
facturer's instructions, the eluted fractions were desalted
and concentrated by centrifugation at 20,000 × g using a
Vivaspin 500 tube (Sartorius, Goettingen, Germany).
SELDI-TOF MS
The SELDI-TOF MS analysis was performed as previously
described [6,8]. Phosphoprotein profiles were obtained
by using the strong anion-exchange arrays (Q10, Bio-
Rad). Immunoprecipitated samples were applied to nor-
mal phase protein array (NP20, Bio-Rad). Each spot of the
array was finally allowed to dry, subsequently two aliq-
uots of 0.5 μl saturated sinapinic acid in 50% acetonitrile
in water containing 0.5% trifluoroacetic acid were applied
on each spot and air-dried.
Phosphatase treatment
Lambda protein phosphatase (λ-PPase; New England
Biolabs, MA, USA), which dephosphorylates all types of
phosphorylated amino acid residues (i.e., p-Ser, p-Thr,
and p-Tyr), was used for dephosphorylation of phospho-
proteins as previously described [6].
Cloning, Construction of Expression Plasmid, and 
Transfection
Human 4E-BP1 cDNA was cloned into the expression vec-
tor pcDNA3.1 (Invitrogen, Carlsbad, USA) to transiently
overexpress the native 4E-BP1 protein in order to enhance
the detection of phosphorylated 4E-BP1 by SELDI-TOF MS
and immunoblotting. A549 cells were selected as hosts to
express the recombinant protein, and were transfected with
the 4E-BP1 expression plasmid using the Lipofectamine
2000 reagent (Invitrogen) as described previously [8].
Immunoprecipitation
Cells expressing the recombinant protein were lysed in a
lysis buffer (50 mM HEPES-NaOH, pH 7.5, 0.5% NP-40,
1 mM sodium orthovanadate, 25 mM sodium fluoride, 15
mM pyrophosphate, and 5 mM EDTA) containing pro-
tease inhibitors [0.1 mM PMSF, 1 μg/ml leupeptin, 1 μg/
ml pepstatin] and incubated for 30 min on ice. The super-
natant obtained after centrifugation at 20,000 × g for 20
min was diluted with the lysis buffer and incubated with
the anti-total-4E-BP1 antibody for 16 h at 4°C, followed
by incubation with the protein G agarose (Upstate, NY,
USA) for 2 hr at 4°C with gentle shaking. The resin was
subsequently washed three times with 10–15 resin vol-
umes of lysis buffer and once with HEPES buffer (20 mM
HEPES, pH 7.5, 50 mM NaCl). Proteins adsorbed to the
resin were eluted by incubation with 5–10 resin volumes
of 0.1 M glycine, pH 2.5 for 15 min on ice. The eluate was
neutralized by the addition of appropriate amount of sat-
urated Tris, and was desalted and concentrated by centrif-
ugation at 20,000 × g using Vivaspin 500 tube.
Immunoblot analysis
Immunoblotting was performed as previously described
[11]. An appropriate Alexa Fluor 680-labeled anti-rabbit
IgG (Invitrogen) was used as a secondary antibody, and
immunoreactive protein bands were analyzed using the
Odyssey infrared imaging system (Li-Cor, Lincoln, NE,
USA).
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